At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With T -Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, and 5 other interventions for Metastatic Melanoma and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This phase I/II trial studies how well genetically modified therapeutic autologous lymphocytes (patient's own white blood cells) followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has spread to other places in the body (metastatic). Placing chemokine (C-X-C motif) receptor 2 (CXCR2) and nerve growth factor receptor (NGFR) into lymphocytes (white blood cells) may help the body build an immune response to kill melanoma cells. Aldesleukin may enhance this effect by stimulating white blood cells to kill more melanoma cells. Giving genetically modified therapeutic autologous lymphocytes together with aldesleukin may be a better treatment for melanoma.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Correlative studies
Given IV
Ancillary studies